378 related articles for article (PubMed ID: 17216850)
1. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
[No Abstract] [Full Text] [Related]
2. Anti-HIV agents. Atazanavir and saquinavir.
TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
[No Abstract] [Full Text] [Related]
3. Anti-HIV agents. Kaletra + atazanavir.
TreatmentUpdate; 2005; 17(5):5. PubMed ID: 17219657
[No Abstract] [Full Text] [Related]
4. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
[No Abstract] [Full Text] [Related]
5. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
Huff B
GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
[No Abstract] [Full Text] [Related]
6. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Cordery DV; Hesse K; Amin J; Cooper DA
Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
[TBL] [Abstract][Full Text] [Related]
7. Boosted Reyataz: 48-week results.
Huff B
GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
[No Abstract] [Full Text] [Related]
8. [Adverse effects of atazanavir].
Palacios R; González M; Ruiz J; Santos J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():41-4. PubMed ID: 20116616
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of atazanavir in simplification regimens].
Zamora L; Gatell JM
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():14-21. PubMed ID: 20116612
[TBL] [Abstract][Full Text] [Related]
10. A new protease inhibitor from Bristol-Myers Squibb.
TreatmentUpdate; 2001; 12(12):5. PubMed ID: 11570092
[No Abstract] [Full Text] [Related]
11. [New protease inhibitor against HIV. Viral load decreases--without lipid increase].
MMW Fortschr Med; 2003 Aug; 145(33-34):61. PubMed ID: 14526586
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
13. [Introduction. Usefulness of atazanavir in the treatment of patients infected by human immunodeficiency virus].
Rivero A
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():1. PubMed ID: 20116609
[No Abstract] [Full Text] [Related]
14. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373065
[No Abstract] [Full Text] [Related]
15. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
Poirier JM; Guiard-Schmid JB; Meynard JL; Bonnard P; Zouai O; Lukiana T; Jaillon P; Girard PM; Pialoux G
AIDS; 2006 Apr; 20(7):1087-9. PubMed ID: 16603872
[No Abstract] [Full Text] [Related]
16. Anti-HIV drug update.
Proj Inf Perspect; 2000 Aug; (30):5-6. PubMed ID: 12171015
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions. Kaletra and atazanavir.
TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
[No Abstract] [Full Text] [Related]
18. Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
Rubio R; Serrano O; Carmena J; Asensi V; Echevarría S; Flores J; Ribera E; Zarraga M; Ocampo A; de la Fuente B; Sepúlveda MA; Mariño AI; Minguez C; Vicent R; Cartón JA; Moyano B; Esteban H; Mahillo B; Serrano L; González-García J;
HIV Med; 2010 Oct; 11(9):545-53. PubMed ID: 20345884
[TBL] [Abstract][Full Text] [Related]
19. Protease inhibitors: opium of the masses?
Martinez LJ
Res Initiat Treat Action; 2000 Sep; 6(3):7-11. PubMed ID: 11708167
[No Abstract] [Full Text] [Related]
20. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
